Log in

Aimmune Therapeutics SEC Filings & 10K Form (NASDAQ:AIMT)

$25.79
+0.64 (+2.54 %)
(As of 10/22/2019 04:42 AM ET)
Today's Range
$25.21
Now: $25.79
$25.82
50-Day Range
$19.18
MA: $22.64
$25.75
52-Week Range
$16.95
Now: $25.79
$36.12
Volume535,680 shs
Average Volume713,730 shs
Market Capitalization$1.62 billion
P/E RatioN/A
Dividend YieldN/A
Beta-0.08

SEC Filings

Aimmune Therapeutics (NASDAQ:AIMT) SEC Filings

DateFilerForm TypeView
09/20/2019
7:55 AM
Aimmune Therapeutics (Issuer)
BJERKHOLT ERIC (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/19/2019
3:05 PM
Aimmune Therapeutics (Issuer)
ENRIGHT PATRICK G (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/13/2019
7:41 PM
Aimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/08/2019
3:14 PM
Aimmune Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/08/2019
3:08 PM
Aimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/18/2019
3:36 PM
Aimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/28/2019
8:22 PM
Aimmune Therapeutics (Issuer)
Behar Gregory (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/28/2019
8:22 PM
Aimmune Therapeutics (Issuer)
MCDADE MARK (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/28/2019
8:22 PM
Aimmune Therapeutics (Issuer)
FALBERG KATHRYN E (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/28/2019
8:19 PM
Aimmune Therapeutics (Issuer)
Seltzer Stacey Denenberg (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/28/2019
8:18 PM
Aimmune Therapeutics (Issuer)
ENRIGHT PATRICK G (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/28/2019
8:17 PM
Aimmune Therapeutics (Issuer)
Iwicki Mark T (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/14/2019
4:03 PM
Aimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/08/2019
3:13 PM
Aimmune Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/08/2019
3:05 PM
Aimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/25/2019
7:16 AM
Aimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/20/2019
8:59 AM
Aimmune Therapeutics (Filer)
Form CT ORDER
03/18/2019
7:30 AM
Aimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/13/2019
12:00 PM
Aimmune Therapeutics (Subject)
Foresite Capital Fund II, L.P. (Filed by)
Form SC 13G/A
02/12/2019
4:07 PM
Aimmune Therapeutics (Subject)
Longitude Capital Partners II, LLC (Filed by)
Form SC 13G/A
02/11/2019
8:24 AM
Aimmune Therapeutics (Subject)
VANGUARD GROUP INC (Filed by)
Form SC 13G/A
02/04/2019
9:07 AM
Aimmune Therapeutics (Subject)
BlackRock Inc. (Filed by)
Form SC 13G/A
01/24/2019
3:06 PM
Aimmune Therapeutics (Issuer)
Oxtoby Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/24/2019
3:05 PM
Aimmune Therapeutics (Issuer)
Oxtoby Andrew (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
01/14/2019
3:01 PM
Aimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/03/2018
1:17 PM
Aimmune Therapeutics (Subject)
Nestle Health Science US Holdings, Inc. (Filed by)
Form SC 13D/A
11/29/2018
10:04 AM
Aimmune Therapeutics (Filer)
Form D
Notice of Exempt Offering of Securities 
11/28/2018
3:10 PM
Aimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/21/2018
3:05 PM
Aimmune Therapeutics (Issuer)
Barrowcliffe Susan E. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/19/2018
7:12 PM
Aimmune Therapeutics (Issuer)
Dallas Jayson Donald Alexander (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/19/2018
5:12 AM
Aimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/13/2018
5:12 AM
Aimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/08/2018
3:20 PM
Aimmune Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/08/2018
3:14 PM
Aimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/07/2018
3:05 PM
Aimmune Therapeutics (Issuer)
HAUMANN BRETT K (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
11/06/2018
4:01 PM
Aimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/08/2018
3:25 PM
Aimmune Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/08/2018
3:20 PM
Aimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/03/2018
12:51 PM
Aimmune Therapeutics (Filer)
Form CT ORDER
06/19/2018
6:06 PM
Aimmune Therapeutics (Issuer)
Dallas Jayson Donald Alexander (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/19/2018
6:03 PM
Aimmune Therapeutics (Issuer)
Dallas Jayson Donald Alexander (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
06/14/2018
3:08 PM
Aimmune Therapeutics (Issuer)
BJERKHOLT ERIC (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2018
3:06 PM
Aimmune Therapeutics (Issuer)
DILLY STEPHEN GEORGE (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2018
3:07 PM
Aimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/08/2018
4:50 PM
Aimmune Therapeutics (Issuer)
DILLY STEPHEN GEORGE (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2018
6:20 PM
Aimmune Therapeutics (Issuer)
DILLY STEPHEN GEORGE (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/25/2018
8:00 AM
Aimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/24/2018
4:09 PM
Aimmune Therapeutics (Issuer)
ENRIGHT PATRICK G (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/24/2018
4:09 PM
Aimmune Therapeutics (Issuer)
Sheehy Douglas T. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/24/2018
4:09 PM
Aimmune Therapeutics (Issuer)
Seltzer Stacey Denenberg (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/24/2018
4:08 PM
Aimmune Therapeutics (Issuer)
Behar Gregory (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/24/2018
4:06 PM
Aimmune Therapeutics (Issuer)
Iwicki Mark T (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/24/2018
4:06 PM
Aimmune Therapeutics (Issuer)
FALBERG KATHRYN E (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/24/2018
4:05 PM
Aimmune Therapeutics (Issuer)
MCDADE MARK (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/08/2018
3:11 PM
Aimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/11/2018
3:08 PM
Aimmune Therapeutics (Filer)
Form DEFA14A
04/11/2018
3:05 PM
Aimmune Therapeutics (Filer)
Form DEF 14A
03/27/2018
3:10 PM
Aimmune Therapeutics (Filer)
Form CT ORDER
03/16/2018
9:58 AM
Aimmune Therapeutics (Filer)
Form D
Notice of Exempt Offering of Securities 
03/12/2018
4:00 PM
Aimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/06/2018
7:42 PM
Aimmune Therapeutics (Issuer)
Barrowcliffe Susan E. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2018
7:42 PM
Aimmune Therapeutics (Issuer)
Knapp Jeffrey H (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2018
7:41 PM
Aimmune Therapeutics (Issuer)
Rozenman Mary M. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2018
7:40 PM
Aimmune Therapeutics (Issuer)
Sheehy Douglas T. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2018
7:40 PM
ADELMAN DANIEL C MD (Reporting)
Aimmune Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2018
7:39 PM
Aimmune Therapeutics (Issuer)
BJERKHOLT ERIC (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2018
3:05 PM
Aimmune Therapeutics (Issuer)
Rozenman Mary M. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/26/2018
3:25 PM
Aimmune Therapeutics (Issuer)
Tammenoms Bakker Juliet (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/26/2018
3:22 PM
Aimmune Therapeutics (Issuer)
ENRIGHT PATRICK G (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/26/2018
3:05 PM
Aimmune Therapeutics (Issuer)
Iwicki Mark T (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/26/2018
3:05 PM
Aimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/26/2018
3:05 PM
Aimmune Therapeutics (Issuer)
FALBERG KATHRYN E (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/26/2018
3:05 PM
Aimmune Therapeutics (Issuer)
BJERKHOLT ERIC (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/22/2018
3:32 PM
Aimmune Therapeutics (Filer)
Form 424B5
02/20/2018
4:06 PM
Aimmune Therapeutics (Filer)
Form 424B5
02/20/2018
3:06 PM
Aimmune Therapeutics (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
02/20/2018
6:01 AM
Aimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/13/2018
11:25 AM
Aimmune Therapeutics (Subject)
Foresite Capital Fund II, L.P. (Filed by)
Form SC 13G/A
02/08/2018
9:54 AM
Aimmune Therapeutics (Subject)
VANGUARD GROUP INC (Filed by)
Form SC 13G
02/05/2018
3:05 PM
Aimmune Therapeutics (Issuer)
Rozenman Mary M. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/01/2018
8:24 AM
Aimmune Therapeutics (Subject)
BlackRock Inc. (Filed by)
Form SC 13G
01/26/2018
4:32 PM
Aimmune Therapeutics (Issuer)
Sheehy Douglas T. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/16/2018
5:05 PM
ADELMAN DANIEL C MD (Reporting)
Aimmune Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/10/2018
3:05 PM
Aimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/08/2018
3:07 PM
Aimmune Therapeutics (Issuer)
Sheehy Douglas T. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/08/2018
7:30 AM
Aimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/29/2017
4:26 PM
ADELMAN DANIEL C MD (Reporting)
Aimmune Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/28/2017
4:45 PM
Aimmune Therapeutics (Issuer)
Rozenman Mary M. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/28/2017
4:43 PM
Aimmune Therapeutics (Issuer)
Sheehy Douglas T. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/28/2017
3:34 PM
Aimmune Therapeutics (Filer)
Form S-3ASR
12/08/2017
3:31 PM
Aimmune Therapeutics (Issuer)
Seltzer Stacey Denenberg (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/06/2017
3:05 PM
Aimmune Therapeutics (Issuer)
Sheehy Douglas T. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/04/2017
3:05 PM
Aimmune Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
This page was last updated on 10/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel